Al Sandrock, Voyager Therapeutics CEO

No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

No­var­tis has lined up two more neu­ro­log­ic dis­eases in its gene ther­a­py col­lab­o­ra­tion with Voy­ager Ther­a­peu­tics, this time pay­ing about …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.